In 2015, Global Revenue of Drugs for Schistosomiasis is nearly 62 million USD
Thursday, 20 Sep, 2018

In the last several years, Global market of Drugs for Schistosomiasis developed smoothly, with an average growth rate of 9.5%. In 2015, Global Revenue of Drugs for Schistosomiasis is nearly 62 million USD; the actual production is about 1350 million units.


The global average price of Drugs for Schistosomiasis is in the decreasing trend, from 62 USD/K Units in 2011 to 57 USD/K Units in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.


The classification of Drugs for Schistosomiasis is Praziquantel, Oxamniquine and other. Praziquantel is the mainly drug for Schistosomiasis, and the proportion of Praziquantel in 2015 is about 90%.

Drugs for Schistosomiasis are widely used in S. haematobium, S. mansoni, S. japonicum, S. mekongi and S. intercalatum.Most of human infections are caused by S. haematobium, S. mansoni, S. japonicum. And the market share used in S. haematobium in 2015 is 28%. And the market share used in S. mansoni in 2015 is 48%. 


Rest of Asia region is the largest supplier of Drugs for Schistosomiasis, with a production market share nearly 63.1% in 2015.


East Africa is the largest consumption place, with a consumption market share nearly 23.8% in 2015. Following East Africa, West Africa is the second largest consumption place with the consumption market share of 20.6% in 2015.


Market competition is intense among top 3. Shin Poong, Merck, Bayer are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.